Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
← catalyst calendarNCT07087054 · readout ≤ 377 d
Sponsored by Crinetics Pharmaceuticals Inc. (industry) · CRNX — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
141estimated
Sites
67
Countries
Argentina, Brazil, Chile +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-19 | actual | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoid Syndrome
- Carcinoid
- Carcinoid Tumor
- Carcinoid Tumor of Ileum
- Carcinoid Tumor of Cecum
- Carcinoid Tumor of Liver
- Carcinoid Tumor of Pancreas
- Carcinoid Syndrome Diarrhea
- Carcinoid Intestine Tumor
Interventions
- Drug: Paltusotine
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFParticipants will record the number of flushing per day in a daily diary to assess the efficacy of paltusotine vs placebo in reducing flushing episodes.
measured Measured at Week 12
Permalink · CRNX's whole pipeline · Catalyst calendar · Every registered study · What changed